 Prescription drugs have become a significant public health concern, with overtreatment and misuse leading to an alarming number of deaths. The increasing death rate from these drugs is particularly concerning given that many of these fatalities are preventable. The Scale of the ProblemIn 2013, it was estimated that prescription drugs were the third leading cause of death in the United States, following heart disease and cancer. By 2015, it was noted that psychiatric drugs alone also ranked as the third leading cause of death. However, some estimates place prescription drugs as the fourth leading cause, based on a 1998 meta-analysis that primarily considered in-hospital adverse drug reactions. This analysis likely underestimates the true extent of the problem since most drug-related deaths occur outside of hospitals and involve complications that are not always correctly attributed to drug use. Underreported and Misclassified DeathsMany deaths linked to prescription drugs are misclassified as natural or unknown causes. This issue is particularly prevalent with psychiatric drugs, where sudden deaths in young patients are often labeled as natural despite known risks of fatal heart arrhythmias from neuroleptics. Similarly, deaths from depression drugs in the elderly, caused by falls and fractures, often go unrecognized as drug-related. Specific Drug Categories and Risks
Increasing PolypharmacyPolypharmacy, the use of multiple medications by a single patient, has been on the rise, especially among the elderly. This trend increases the risk of adverse drug interactions and fatalities. For example, combining benzodiazepines with neuroleptics significantly raises mortality rates. Estimates of Annual Drug-Related DeathsCurrent estimates suggest that over 882,000 deaths in the United States annually can be attributed to prescription drugs. This figure includes hospital deaths, psychiatric drug fatalities, opioid overdoses, and deaths from NSAIDs. These numbers highlight the magnitude of the problem and the urgent need for intervention. The Role of Misguided Regulation and Lack of AwarenessThe pharmaceutical industry's influence on drug regulation has led to more permissive policies, exacerbating the issue. Many deaths could be prevented if drugs were prescribed more judiciously. For instance, neuroleptics and antidepressants often show minimal efficacy in trials, yet they are widely prescribed. Similarly, NSAIDs are commonly recommended despite their significant risks, often without sufficient consideration of safer alternatives. The pervasive issue of prescription drug-related deaths necessitates a reevaluation of current medical practices and regulatory policies. With most of these deaths being preventable, a more cautious approach to prescribing and better awareness of the risks associated with these medications could save countless lives. It is crucial for healthcare providers, regulators, and patients to acknowledge the dangers and work towards safer, more effective treatment strategies. In bed with big pharma: A $12 Billion RelationshipA comprehensive analysis by Yale University researchers has revealed that nearly six in ten doctors in the United States have received over $12 billion in payments from pharmaceutical and medical device companies over the past decade. This study sheds light on the pervasive financial relationships between healthcare providers and the medical industry, highlighting potential conflicts of interest. Key Findings from the Study
Largest Recipients by SpecialtyOrthopedic surgeons topped the list, receiving the highest total sum of payments at $1.36 billion. They were followed by:
 most profitable Drugs and Devices
 most prescribed drugsEvery day, millions of people in the U.S. take prescribed drugs in an effort to help them live their lives. As our understanding of medicine has evolved, we’ve developed drugs to aid with some of the most common medical conditions—from pain and blood pressure drugs to asthma medication, thyroid treatments, and antidepressants. This analysis uses prescribed medicines data from the U.S. Agency for Healthcare Research and Quality, released in 2021 for the 2019 calendar year. It also uses supporting drug and health information from MedlinePlus. Top 10 Most Prescribed Drugs in America (2019)
The most prescribed drug, atorvastatin (sold under the brand name Lipitor), was prescribed to 24.5 million people in the U.S. in 2019, or 7.5% of the population. It was one of many statin medications listed, which are claimed to prevent cardiovascular disease and treat abnormal lipid levels. Prevalent Conditions Treated Most of the top prescribed drugs are used to treat high blood pressure or symptoms of it. This is significant as 108 million, or nearly half of adults in the U.S., have hypertension or high blood pressure.
Combining the total patients for blood pressure and cholesterol medications covers 33% of the U.S. population. Pain and inflammation medications were the most frequent on the top 30 list, prescribed to 13.6% of people. Drug Spending in the U.S.A drug’s total number of patients doesn’t necessarily reflect its importance or cost. For example, levothyroxine, the fourth-most prescribed drug by total patients, was the second-most prescribed by total prescriptions with 102.6 million in 2019 at an average cost of $25.10 per prescription. More specialized medications like fluticasone had fewer total prescriptions (27.9 million) but a higher average cost of $97.68 per prescription. Prices are influenced by factors like demand, patent status, and healthcare system variations. Implications and ConcernsThe study underscores ongoing concerns about financial conflicts of interest in the medical field. Researchers noted that such payments might influence physician prescribing behavior and potentially undermine patient trust in medical professionals. Despite these concerns, the practice of accepting industry payments remains widespread.  Data Source and MethodologyThe study utilized data from the Open Payments platform, a national database where drug and medical device companies are required to disclose payments made to physicians. This platform aims to increase transparency and help patients make informed decisions about their healthcare providers. FDA recalls and safety concernsIn a related safety concern, the FDA recalled certain Impella devices in December due to a perforation risk that could cause serious injuries or death. This highlights the ongoing need for vigilance regarding the safety of medical devices widely used in clinical practice. ConclusionThis comprehensive analysis by Yale University researchers provides a clear picture of the substantial financial ties between US doctors and the medical industry, emphasizing the need for ongoing scrutiny and transparency. The relationship between healthcare providers and the medical industry is complex and often financially intertwined. While these financial interactions can support medical education and innovation, they also pose significant ethical and practical challenges. Ensuring transparency and addressing potential conflicts of interest are crucial steps toward maintaining the integrity of medical practice and patient trust. referencesGøtzsche PC. Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Health Care. London: Radcliffe Publishing; 2013.
Gøtzsche PC. Deadly Psychiatry and Organised Denial. Copenhagen: People’s Press; 2015. Schroeder MO. Death by Prescription: By one estimate, taking prescribed medications is the fourth leading cause of death among Americans. US News 2016; Sept 27. Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;41:590-600. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–5. FAERS Reporting by Patient Outcomes by Year. FDA 2015;Nov 10. Gøtzsche PC. Mental Health Survival Kit and Withdrawal From Psychiatric Drugs. Ann Arbor: L H Press; 2022. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77-84. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-82. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med 2001;161:2317–23. James JTA. A new, evidence-based estimate of patient harms associated with hospital care. J Patient Saf 2013;9:122-8. Ho JY. Life Course Patterns of Prescription Drug Use in the United States. Demography 2023;60:1549-79. Gøtzsche PC. Long-term use of antipsychotics and antidepressants is not evidence-based. Int J Risk Saf Med 2020;31:37-42. Gøtzsche PC. Long-Term Use of Benzodiazepines, Stimulants and Lithium is Not Evidence-Based. Clin Neuropsychiatry 2020;17:281-3. Forbruget af antipsykotika blandt 18-64 årige patienter, med skizofreni, mani eller bipolar affektiv sindslidelse. København: Sundhedsstyrelsen; 2006. Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open 2014;4:e005535. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934–43. FDA package insert for Risperdal (risperidone). Accessed 30 May 2022. Koponen M, Taipale H, Lavikainen P, et al. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease. J Alzheimers Dis 2017;56:107-18. Whitaker R. Lure of Riches Fuels Testing. Boston Globe 1998; Nov 17. Whitaker R. Mad in America: Bad science, Bad medicine, and the Enduring Mistreatment of the Mentally Ill. Cambridge: Perseus Books Group; 2002:page 269. Vanderburg DG, Batzar E, Fogel I, et al. A pooled analysis of suicidality in double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry 2009;70:674-83. Hengartner MP, Plöderl M. Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: a Re-Analysis of the FDA Database. Psychother Psychosom 2019;88:247-8. Hengartner MP, Plöderl M. Reply to the Letter to the Editor: “Newer-Generation Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s ReAnalysis.” Psychother Psychosom 2019;88:373-4. Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014;348:g1996. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open 2012;2:e000850. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 2009;169:2128-39. O’Neill A. Age distribution in the United States from 2012 to 2022. Statista 2024;Jan 25. Olfson M, King M, Schoenbaum M. Antipsychotic Treatment of Adults in the United States. Psychiatrist.com 2015;Oct 21. Maust DT, Lin LA, Blow FC. Benzodiazepine Use and Misuse Among Adults in the United States. Psychiatr Serv 2019;70:97-106. Brody DJ, Gu Q. Antidepressant Use Among Adults: United States, 2015-2018. CDC 2020; Sept. Centers for Disease Control and Prevention. Leading Causes of Death. 2024; Jan 17. Drug Overdose Deaths. Centers for Disease Control and Prevention 2023; Aug 22. Davis JS, Lee HY, Kim J, et al. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart 2017;4:e000550. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012;32:1491-502. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 2005;352:1092-102. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283–91. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. “Adaptive pathways” to drug authorisation: adapting to industry? BMJ 2016;354:i4437. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006;29:161-8. Gøtzsche PC. Big marketing hoax: Non-steroidal, anti-inflammatory drugs (NSAIDs) are not anti-inflammatory. Copenhagen: Institute for Scientific Freedom 2022;Nov 10. Perlis R. The time has come for over-the-counter antidepressants. Stat News 2024;April 8. Gøtzsche PC. Critical Psychiatry Textbook. Copenhagen: Institute for Scientific Freedom; 2022. Freely available. Tilley, Caitlin. “Corruption Fears as Report Finds US Doctors Received Record $12bn.” Mail Online, 3 Apr. 2024, www.dailymail.co.uk/health/article-13268371/Corruption-doctors-received-pharma-payments.html. Tanne, Janice Hopkins. “US Doctors Received More than $12bn in Industry Payments between 2013 and 2022, Study Shows.” BMJ, vol. 385, 2 Apr. 2024, p. q781, www.bmj.com/content/385/bmj.q781.full, https://doi.org/10.1136/bmj.q781.
0 Comments
Leave a Reply. |
The Awareness domain contains research, news, information, observations, and ideas at the level of self in an effort to intellectualize health concepts.
The Lifestyle domain builds off intellectual concepts and offers practical applications.
Taking care of yourself is at the core of the other domains because the others depend on your health and wellness.
Archives
October 2024
Categories
All
|
RSS Feed
